Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 7,700 shares at $97.52 ($759K) on 2020-02-21, disclosed to the SEC on 2020-02-24.
Open-market sale of $759k RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $97.52 | 1,849 | $180K | 23.7% |
| 2 | $97.52 | 1,849 | $180K | 23.7% |
| 3 | $99.12 | 906 | $90K | 11.8% |
| 4 | $99.12 | 906 | $90K | 11.8% |
| 5 | $99.85 | 945 | $94K | 12.4% |
| 6 | $99.85 | 945 |
| $94K |
| 12.4% |
| 7 | $101.06 | 300 | $30K | 4.0% |
| Total | $98.61 avg | 7,700 | $759K | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |